FDA Issues Paper: Data & Methods For Evaluating The Impact Of Opioid Formulations With Properties Designed To Deter Abuse In The Postmarket Setting
On June 14, 2017, the Federal Food and Drug Administration (FDA) released this paper regarding data and methods for evaluating the impact of opioid formulations with properties designed to deter abuse in the postmarket setting. The paper is being presented prior to the July 10 and 11, 2017 public meeting . . .